Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases

Neurological Research

Volumn 30, Issue 4, 2008, Pages 366-369

  Li, Zhen Guang ^a   Yu, Zhan Cai ^a   Wang, Dao Zhen ^a   Ju, Wei Ping ^a   Zhan, Xia ^a   Wu, Qi Zhuan ^b   Wu, Xi Juan ^a   Cong, Hai Ming ^a   Man, Hong Hao ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Ischemic stroke; Lysophosphatidic acid; Platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; LYSOPHOSPHATIDIC ACID; PHOSPHORUS DERIVATIVE;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BRAIN ISCHEMIA; DOWN-REGULATION; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; PHOSPHORUS; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 45849092920     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X300369     Document Type: Article

References (25)

1. Lyncha KR, Macdonald TL. Structure-activity relationships of lysophosphatidic acid analogs. Biochim Biophys Acta 2002; 1582: 289-294
2. Eichholtz T, Jalink K, Fahrenfort I, et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-680
3. Moolenar WH. Lysophosphatid acid, a multifunctional phospholid messenger. J Biol Chem 1995; 270: 12949-12952
4. Mauco G, Chap H, Simon MF, et al. Phosphatidic and lysophosphatidic acid production in phospholipase C and thrombin-treated platelets. Possible involvement of a platelet lipase. Biochimie 1978; 60: 653-661
5. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta 1989; 1001: 282-285
6. Eichholtz T, Jalink K, Fahrenfort I, et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-680
7. Sano T, Baker DL, Virag T, et al. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 2002; 277: 21197-21206
8. Motohashi K, Shibata S, Ozaki Y, et al. Identification of lysophospholipid receptors in human platelets: The relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. FEBS Lett 2000; 468: 189-193
9. Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-2574
10. Karliner JS. Lysophospholipids and the cardiovascular system. Biochim Biophys Acta 2002; 1582: 216-221
11. Barnett HJ, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238-248
12. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218
13. Johnston SC. Clinical practice. Transient ischemic attack. N Engl J Med 2002; 347: 1687-1692
14. Bravata DM, Ho SY, Brass LM, et al. Long-term mortality in cerebrovascular disease. Stroke 2003; 34: 699-704
15. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: Scientific review. JAMA 2002; 288: 1388-1395
16. Diener HC. Aspirin therapy should be first-line treatment in secondary prevention of stroke - against. Stroke 2002; 33: 2138-2139
17. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106
18. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001; 119 (Suppl. 1): S39-S63
19. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655
20. Aoki J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 2002; 277: 48737-48744
21. Sun YH, Wu QZ, Huang SC, et al. A preliminary study of the level of plasma lysophosphatidic acid (LPA) in patients with cerebral ischemic attack. Chin J Med 2002; 82: 229-231
22. Sabbadini RA, Deutschman DH, Carstens JS, et al. The MIRF trial: Predicting the incidence and severity of chronic ischemic heart disease using serum sphingolipids. Circulation 2000; 102 (Suppl. II): S699
23. Meyer zu Heringdorf D, Himmel HM, Jakobs KH. Sphingosylphosphorylcholine- biological functions and mechanisms of action. Biochim Biophys Acta 2002; 1582: 178-189
24. Rother E, Brandl R, Baker DL, et al. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003; 108: 741-747
25. Spector AA. Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation 2003; 108: 641-643